Biocon has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the Post-Approval and GMP inspection of its Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, conducted between Feb 20 and Feb 26, 2020. The EIR has been closed with a 'VAI' classification for the observations. At the conclusion of the inspection last month the agency had issued a Form 483, with two observations, which were procedural in nature and are being addressed by the Company.
We remain committed to global standards of Quality and Compliance." - Company Spokesperson.
Shares of BIOCON LTD. was last trading in BSE at Rs.252.55 as compared to the previous close of Rs. 252. The total number of shares traded during the day was 930792 in over 6634 trades.
The stock hit an intraday high of Rs. 264.9 and intraday low of 235.8. The net turnover during the day was Rs. 239865169.